Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients. by Sass, Lucas R et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
1-21-2020 
Non-invasive MRI quantification of cerebrospinal fluid dynamics in 
amyotrophic lateral sclerosis patients. 
Lucas R Sass 
Mohammadreza Khani 
Jacob Romm 
Marianne Schmid Daners 
Kyle McCain 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Neurosciences Commons 
Authors 
Lucas R Sass, Mohammadreza Khani, Jacob Romm, Marianne Schmid Daners, Kyle McCain, Tavara 
Freeman, Gregory T Carter, Douglas L Weeks, Brian Petersen, Jason Aldred, Dena Wingett, and Bryn A 
Martin 
Sass et al. Fluids Barriers CNS            (2020) 17:4  
https://doi.org/10.1186/s12987-019-0164-3
RESEARCH
Non-invasive MRI quantification 
of cerebrospinal fluid dynamics in amyotrophic 
lateral sclerosis patients
Lucas R. Sass1†, Mohammadreza Khani1†, Jacob Romm1,2, Marianne Schmid Daners3, Kyle McCain1, 
Tavara Freeman1, Gregory T. Carter4, Douglas L. Weeks4, Brian Petersen5, Jason Aldred6, Dena Wingett7 
and Bryn A. Martin1,8* 
Abstract 
Background: Developing novel therapeutic agents to treat amyotrophic lateral sclerosis (ALS) has been difficult due 
to multifactorial pathophysiologic processes at work. Intrathecal drug administration shows promise due to close 
proximity of cerebrospinal fluid (CSF) to affected tissues. Development of effective intrathecal pharmaceuticals will 
rely on accurate models of how drugs are dispersed in the CSF. Therefore, a method to quantify these dynamics and a 
characterization of differences across disease states is needed.
Methods: Complete intrathecal 3D CSF geometry and CSF flow velocities at six axial locations in the spinal canal 
were collected by T2-weighted and phase-contrast MRI, respectively. Scans were completed for eight people with ALS 
and ten healthy controls. Manual segmentation of the spinal subarachnoid space was performed and coupled with 
an interpolated model of CSF flow within the spinal canal. Geometric and hydrodynamic parameters were then gen-
erated at 1 mm slice intervals along the entire spine. Temporal analysis of the waveform spectral content and feature 
points was also completed.
Results: Comparison of ALS and control groups revealed a reduction in CSF flow magnitude and increased flow 
propagation velocities in the ALS cohort. Other differences in spectral harmonic content and geometric comparisons 
may support an overall decrease in intrathecal compliance in the ALS group. Notably, there was a high degree of vari-
ability between cases, with one ALS patient displaying nearly zero CSF flow along the entire spinal canal.
Conclusion: While our sample size limits statistical confidence about the differences observed in this study, it was 
possible to measure and quantify inter-individual and cohort variability in a non-invasive manner. Our study also 
shows the potential for MRI based measurements of CSF geometry and flow to provide information about  the hydro-
dynamic environment of the spinal subarachnoid space. These dynamics may be studied further to understand the 
behavior of CSF solute transport in healthy and diseased states.
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Background
Amyotrophic lateral sclerosis (ALS), also known as Lou 
Gehrig’s disease, is a devastating neurological disor-
der of predominately sporadic origin [1] that leads to 
severe disability and death. While the majority of cases 
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are sporadic, approximately 10% show familial inherit-
ance [2]. ALS results in the loss of upper and lower motor 
neurons from the motor cortex, brainstem and spinal 
cord. Neurodegeneration in ALS typically advances in a 
sequential fashion to the point of phrenic nerve involve-
ment resulting in failure of respiratory effort and death 
before degenerative changes are seen elsewhere [3]. ALS 
affects approximately 3.9 in 100,000 people within the 
United States [4] with approximately equal occurrence 
worldwide and does not appear to be linked with envi-
ronmental toxins. Studies indicate that ALS incidence is 
approximately 1.8 times greater in males than females for 
unknown reasons [5].
A current challenge in identifying treatments for ALS 
is finding reliable measures of efficacy. Historically, sur-
vivability is one of the main metrics used in this deter-
mination [6]. Through examination of the CSF system we 
aim to add to the understanding of ALS pathophysiology 
and potentially provide another avenue of diagnosing or 
monitoring the disease in a quantitative manner. Devel-
oping novel therapeutic agents to treat ALS has also 
been difficult because of the high degree of disease het-
erogeneity and multifactorial pathophysiologic processes 
at work [6, 7]. A growing area of research surrounding 
ALS treatment is intrathecal (IT) drug administration. 
Researchers have investigated safety, tolerability, and 
pharmacodynamics of IT injection for a range of ALS 
therapeutics [6]. Additionally, filtration of cerebrospinal 
fluid (CSF) is actively being developed as a treatment for 
cryptococcal meningitis [8], subarachnoid hemorrhage 
[9] and has been used experimentally in ALS [10, 11].
To be effective, delivery of IT therapies rely on trans-
port within CSF, movement of the drug across the menin-
ges, transport along the perivascular spaces and finally 
absorption into CNS tissue. The use of in vivo measure-
ments along with computer models of CSF solute trans-
port could help maximize drug dispersion and help avoid 
toxicity. Magnetic resonance imaging (MRI) is an effec-
tive tool for non-invasively measuring CSF flow. Several 
studies have already used phase contrast MRI (PCMRI) 
to measure and reconstruct CSF flow dynamics in silico 
[12–14].
The goal of the present study was to characterize CSF 
flow dynamics and geometry in people with ALS com-
pared to healthy controls. A few groups have made strides 
towards characterizing CSF dynamics in conditions such 
as Chiari malformation [15–21], Syringomyelia [20–22], 
and hydrocephalus [23], as well as investigation of CSF 
flow dynamics in people with ALS [24]. We expand on 
this characterization by providing a more complete anal-
ysis of the hydrodynamic environment. Consideration of 
hydrodynamics could aid in development of emerging 
therapeutics while also expanding the pathophysiologic 
understanding of this disease.
Methods
Inclusion criteria for people with ALS were diagnosis of 
clinically suspected or definite ALS and able to tolerate 
the MRI scan without contraindications. Exclusion crite-
ria included: presence of connective tissue disorder, pre-
vious history of cardiovascular disease, intracranial mass/
deformity, CSF leak, spinal cord tethering, spina bifida, 
or myelomeningocele. Ultimately, eight participants with 
ALS were recruited from a regional adult population. The 
size of this population and restriction on travel compen-
sation further limited recruitment of people with ALS 
in this pilot study. Ten healthy adult controls were also 
recruited based on the same exclusion criteria and the 
inclusion criterion of tolerance for the MRI scan without 
contraindications. Prior to each MRI scan, subject height, 
weight, waist circumference, heart rate, and blood pres-
sure were recorded. MRI data collection was performed 
at Inland Imaging in Spokane, WA.
MRI CSF flow measurement protocol
MRI measurements were obtained on a Siemens 3T 
Skyra (Software version syngo MR E11, Siemens Cor-
poration, Munich, Germany). Identical CSF flow meas-
urements were taken for all subjects at six vertebral 
locations, Foramen Magnum (FM), C2–C3, C5–C6, 
T4–T5, T11–T12, and L3–L4 using PCMRI with retro-
spective gating from pulse oximetry for 30 cardiac phases 
(Fig. 1a). Slice thickness at each location was 5.0 mm with 
an in-plane isotropic resolution of 781  µm (~ 150 × 200 
pixel FOV). Each slice was oriented perpendicular to the 
direction of CSF flow with slice plane aligned at the loca-
tion of the vertebral disks (Fig.  1d). Values used for the 
flip angle, TR, TE, and VENC were 20°, 20.34, 6.69 and 
10 cm/s, respectively. Total imaging time to collect all six 
slices was ~ 10 min.
CSF flow quantification
The CSF flow rate, QCSF (t) , was calculated for each of 
the six spinal locations shown in Fig.  1d by importing 
the PCMRI data into MATLAB R2016b (The Math-
works Inc., Natick, MA, USA). QCSF (t) was computed 
based on the numerical integration of individual pixel 
velocities over the CSF area ( ACSF  ) for an entire car-
diac cycle: QCSF (t) =
∑
Avoxel[vvoxel(t)] , where Avoxel is 
the in-plane area of one PCMRI voxel, and vvoxel is the 
CSF velocity encoded in that voxel (Fig.  1b). The CSF 
waveform for the entire spinal cord (SC) was derived 
through interpolation of CSF flow between each of 
the six axial measurements. Methods were previously 
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developed by our group for calculating CSF and cere-
bral blood flow rates [15, 25] as well as CSF flow inter-
polation [13, 26].
MRI CSF space geometry protocol
A stack of high-resolution sagittal T2-weighted sam-
pling perfection with application optimized contrasts 
using different flip angle evolution (SPACE) magnetic 
resonance (MR) images of the complete spinal suba-
rachnoid space (SSS) anatomy was acquired for each 
subject (Fig.  1d). These images were acquired with 
437 µm isotropic in-plane resolution with 800 µm slice 
thickness and spacing in three blocks (craniocervical, 
thoracic, and lumbosacral). Total imaging time for both 
MRI scan types was ~ 42 min.
CSF space segmentation
The segmentation of MRI data was performed using 
the open-source program, ITK-SNAP (Version 3.4.0, 
University of Pennsylvania, USA). The MR image set 
for each spinal segment was manually reconstructed 
from an axial view with the semi-automatic contrast-
based segmentation tool (Fig. 1c), as performed by our 
group in previous work [17]. Segmentation from the 
FM to the end of the dural sac was completed by one of 
two trained operators (Figs. 1e and 2). Anatomical fine 
structures such as SC nerve roots (except at the filum 
terminale) and denticulate ligaments were not pos-
sible to accurately visualize, given the MRI resolution 
with which the scans were collected. Consequently, 
these structures were not included in the segmentation 
(Fig. 1e).
Fig. 1 Subject specific example of CSF flow and geometric reconstruction for control 008. a Phase-contrast MRI at each of the six axial locations 
along the spine. b CSF flow rate based on PCMRI measurements collected at the FM, C2–C3, C5–C6, T4–T5, T11–T12, and L3–L4. c Axial view of 
semi-automatic contrast-based segmentation of T2-weighted MRI slices. d Full spine sagittal T2-weighted MR image including the position of axial 
segments of interest. e Final 3D geometric model of the SSS
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Geometric analysis
Similar to our previous studies, computational meshing 
was used to calculate the following geometric parameters 
along the spine [27]: First, the cross-sectional area of the 
SC, Ac , and region bounded by the dura, Ad, were used to 
obtain the cross-sectional area of the SSS, Acs = Ad−Ac . 
The hydraulic diameter for internal flow within a tube, 
DH = 4Acs/Pcs , was calculated based on the cross-sec-
tional area and wetted perimeter, Pcs = Pd + Pc . Wetted 
perimeter is the sum of the SC, Pc, and dura, Pd, perime-
ter. A user-defined function was used to calculate each of 
these parameters in ANSYS FLUENT (Ver. 19.2, ANSYS 
inc, Canonsburg, PA, USA).
Hydrodynamic analysis
Hydrodynamic environment was assessed at 1-mm slice 
intervals along the entire spine by Reynolds number 
based on the peak flow rate, and Womersley number 
based on hydraulic diameter. In calculating Reynolds 
number, Re = QsysDH
νAcs
 , Qsys is the temporal maximum 
of the local flow at each axial location along the spine 
obtained by interpolation from the experimental data. 
The kinematic viscosity of CSF, given by ν = µ/ρ , was 
assumed to be the same as water at body temperature. At 
peak systole, the presence of laminar flow along the spine 
was characterized using Reynolds number (Re < 2300) 
similar to previous studies in CSF mechanics [13, 17, 26]. 
The Womersley number, α = DH
√
ω/ν , was computed 
where ω is the angular velocity of the volumetric flow 
waveform with ω = 2/T  and ν is the kinematic viscosity 
of CSF as defined above. The Womersley number can be 
used to characterize the ratio of unsteady inertial forces 
to viscous forces for the CSF of the SSS [28]. CSF pulse 
wave velocity ( PWV  ) along the spine was quantified as 
a possible indicator of SSS compliance, as performed in 
our previous studies [13, 26]. In brief, a linear fit of the 
peak systolic flow arrival time along the spine was used to 
compute PWV  , equal to the slope of the linear fit.
CSF waveform analysis
For flow rate and frequency analysis, it was necessary to 
perform normalization and alignment of the flow data. 
CSF flow rate at each of the six axial measurement loca-
tions were offset-corrected such that the net flow rate 
corresponded to 0  mL/s. Average flow rate was calcu-
lated for the C2–C3 location [29]. Because of disparate 
temporal offsets introduced by the use of pulse oximetry 
in PCMRI phase gating, the steepest decent assessed at 
the C2–C3 location was used to align the data in time. 
This phase shift was done on a subject-specific basis 
with the time shift value calculated at the C2–C3 loca-
tion applied across all locations. The data was then 
extended to 1280  ms during diastole and resampled at 
Fig. 2 Geometric models of the spinal subarachnoid space for all subjects created by an expert operator based on T2-weighted MRI data 
segmentation. ALS subject 104 is not included as they withdrew from the study before collection of MRI data
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10-ms intervals to avoid influencing the fast Fourier 
transformation (FFT) and to allow temporal comparison 
across all subjects. The cardiac cycle over all subjects was 
956 ± 138 ms and the longest duration was 1264 ms. For 
the frequency analysis, the data at all six axial locations 
was spatially normalized by the average flow rate at the 
C2–C3 location with the goal to emphasize the flow pat-
terns at all locations rather than to assess the individual 
flow rates. The frequency components of the FFT are 
expressed in harmonics (−). The data analysis and visu-
alization were performed within MATLAB R2016b.
Statistical analysis
Descriptive statistics were obtained for each parameter 
analyzed in terms of mean and standard deviation of val-
ues at each axial location for the ALS and control groups. 
Average values over the entire spine were also computed 
for each parameter along with the total value for param-
eters such as total spinal cord, dura and SSS volume. 
Statistical analysis was conducted in MATLAB R2016b. 
Feature points and the individual frequency compo-
nents were statistically  compared with a Mann–Whit-
ney U test. Differences were considered significant at a 
p-value < 0.05.
Results
The ALS group was comprised of 7 males and 1 female 
with average age of 56 ± 10  years. The control group 
included 6 males and 4 females averaging 59 ± 12  years 
of age. The tabulated results for all parameters quantified 
in the ALS group and corresponding values in the con-
trol group may be found in Table 1. MR images of healthy 
controls revealed no major abnormalities, such as degen-
erate disks or CSF stenoses that would be considered 
to affect CSF flow dynamics or geometry. One person 
with ALS (101) had a nonfunctioning IT pain medica-
tion pump and two ALS patients (106 and 108) had a 
history of spinal surgery (laminectomy and L4–S1 spi-
nal fusion respectively). These subjects were included in 
our final ALS cohort as no anomalies were present in the 
SSS geometry. Another person with ALS (102) had near 
zero flow at all locations and was therefore excluded from 
the flow and hydrodynamic analyses (Figs. 4, 5, 6, 7). In 
the case of near zero flow, we confirmed that the PCMRI 
sequence triggered correctly by verification of pulsatile 
arterial and venous blood flow patterns to the brain vis-
ible in the imaging.
Geometric parameters
Visual inspection of the geometries showed a similar 
appearance in terms of shape between ALS patients and 
controls. One ALS subject (102) had a focal decrease 
in SSS cross-sectional area (Fig.  2). Quantitatively, 
cross-sectional area of the dura was found to be 11% 
smaller in the ALS group with the greatest differ-
ence tending to be within the dural sac region (Fig. 3a). 
Note,  parameters are plotted with respect to  their nor-
malized axial distance below the foramen magnum. 
Axial SC area was nearly identical for the two groups 
(0.35 cm2, Fig. 3b and Table 1). The ALS group had a 14% 
smaller cross-sectional SSS area than the healthy controls 
(1.53 cm2 and 1.78 cm2 respectively, Fig. 3c and Table 1). 
Similarly, the perimeter of the dura and SSS also tended 
to be slightly smaller in the ALS group compared to 
healthy controls within the dural sac region (Fig.  3d, f ). 
No difference was observed in the perimeter of the SC 
(Fig. 3e). Average volume (Table 1) of the SSS in the ALS 
group (97.3  cm3) was 10% less than the control group 
(108.2 cm3).
CSF flow characteristics
All flow rates from the PCMRI data measured at the FM, 
C2–C3, C5–C6, T4–T5, T11–T12, and L3–L4 vertebral 
locations are plotted for both the control (blue) and ALS 
(red) groups, excluding ALS case 102 in Fig. 4. Compared 
to the control group, peak systolic CSF flow in the ALS 
group was larger at C2–C3, comparable at FM, C5–C6, 
Table 1 Geometric and hydrodynamic results
DM dura matter, PWV pulse wave velocity, SC spinal cord, SSS spinal 
subarachnoid space, Qdia average diastolic CSF flowrate, Qsys average systolic CSF 
flowrate, Usys average systolic CSF velocity, Udia average diastolic CSF velocity
a Average values are based 1 mm slice intervals along the entire spine
Parameter Control
Avg.a ± std.
ALS
Avg.a ± std.
Perimeter SC (cm) 1.87 ± 0.22 1.88 ± 0.26
Perimeter DM (cm) 5.66 ± 0.78 5.25 ± 0.83
Perimeter SSS (cm) 7.53 ± 0.89 7.13 ± 0.96
Cross-sectional area SC  (cm2) 0.35 ± 0.07 0.35 ± 0.08
Cross-sectional area DM  (cm2) 2.13 ± 0.54 1.89 ± 0.49
Cross-sectional area SSS  (cm2) 1.78 ± 0.53 1.53 ± 0.48
Volume SC  (Vc)  (cm
3) 20.99 ± 2.55 22.53 ± 2.29
Volume DM  (Vd)  (cm
3) 129.19 ± 18.67 119.83 ± 21.74
Volume SSS  (Vcs)  (cm
3) 108.20 ± 18.67 97.30 ± 20.51
Surface area SC  (cm2) 113.52 ± 7.67 119.37 ± 6.59
Surface area DM  (cm2) 344.12 ± 27.30 333.54 ± 39.72
Surface area SSS  (cm2) 457.64 ± 29.89 452.91 ± 43.82
Hydraulic diameter (cm) 0.96 ± 0.21 0.89 ± 0.21
Reynolds number (cm) 194.74 ± 80.75 209.37 ± 37.34
Womersley number (α) 12.71 ± 1.48 11.92 ± 1.51
Usys (cm/s) − 1.30 ± 0.34 − 1.29 ± 0.33
Udia (cm/s) 0.76 ± 0.30 0.70 ± 0.28
Qsys  (cm
3/s) − 1.88 ± 0.62 − 1.58 ± 0.31
Qdia  (cm
3/s) 1.06 ± 0.29 0.83 ± 0.17
PWV (cm/s) 347.41 ± 88.13 473.19 ± 162.04
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T4–T5 and T11–T12, and smaller at L3–L4. Only the 
feature point of the FM peak systolic CSF flow was sig-
nificantly faster between the two groups (p = 0.0136). The 
maximum peak systolic CSF flow feature points assessed 
for every subject individually, again excluding ALS case 
102 as noted above, are marked at their mean with the 
corresponding standard deviation error bars regarding 
timing and flow in Fig. 4.
Average CSF PWV along the spine was 36% faster in 
the ALS group (473 cm/s) compared to the control group 
(347  cm/s) (Table  1). The average spatial–temporal dis-
tribution of the CSF PWV for all ALS subjects exclud-
ing 102, and controls is shown in Fig.  5. Peak systolic 
CSF flow magnitude occurred at a normalized distance 
of ~ 0.05 below the FM in patients and ~ 0.2 in controls 
(Fig. 5).
Fig. 3 Average geometric parameter values for the ALS group (red) plotted with those of the control group (blue) in relation to distance from the 
FM in terms of: a cross-sectional area of dura, b cross-sectional area of spinal cord, c cross-sectional area of the subarachnoid space, d perimeter of 
dura, e perimeter of spinal cord, f perimeter of subarachnoid space. Parameters are plotted with respect to their normalized axial distance below 
the forament magnum
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Spectral analysis revealed that the frequency compo-
nents of the normalized flow rate for the ALS (red) and 
the control (blue) groups are significantly different  (*) 
for the first, second, sixth and seventh harmonic of the 
T11–T12 location (p = 0.0031, p = 0.0136, p = 0.0097, 
and p = 0.0330), and for the sixth harmonic of the L3–L4 
location (p = 0.0330). The frequency components are pre-
sented from the first to the seventh harmonic in Fig. 6.
Hydrodynamic parameters
All hydrodynamic parameters of interest for both the 
ALS group, excluding subject 102, and the  control 
group are shown in Fig. 7 and Table 1. The systolic and 
diastolic CSF flow velocity along the length of the spinal 
cord tended to be smaller for the ALS group compared 
to the control group except for immediately inferior 
to the FM and near the dural sac (Fig.  7a). Consider-
ing both CSF geometry and velocity, the average peak 
systolic flow in the ALS group was 16% less than that 
of the control group. The average peak diastolic flow 
in the ALS group was 21% less than the control group 
(Fig.  7b). Reynolds number for the control group was 
194.74 and 209.35 in the ALS group indicating laminar 
flow in both groups. Reynolds number was greater  for 
the ALS group at a normalized distance of ~ 0.1 below 
the FM and again at ~ 0.9 (Fig.  7c). On average, HD in 
the ALS group was 7% smaller at .89  cm vs .96  cm in 
the control group. Womersley number behaved in a 
similar manner between groups for the length of the SC 
(Fig. 7d, right y-axis label).
Discussion
The present study quantified geometric parameters 
in the spinal canal of eight people with ALS and ten 
healthy controls. CSF hydrodynamics were also possible 
to quantify and compare in seven people with ALS and 
ten healthy controls. This section includes the findings 
we feel warrant further investigation as they may have an 
Fig. 4 Flow rates of all subjects at the six axial locations along the spine for the ALS (red) and the control (blue) groups. The respective mean 
flow rate over the ALS and the control group are depicted in the bold lines. The feature points are marked at the peak systolic CSF flow with the 
corresponding standard deviation error bars regarding timing and flow. The FM’s peak systolic CSF flow is significantly different between the two 
groups regarding timing (p = 0.0136) as evaluated by the Mann–Whitney U test. Note that the y-axis scale for T11–T12 and L3–L4 are different from 
the other four axial locations
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Fig. 5 Spatial–temporal distribution of the interpolated CSF flow rates along the length of the spinal canal in the healthy control and ALS groups
Fig. 6 Frequency components of the normalized flow rate at the six axial locations along the spine for the ALS (red) and the healthy control (blue) 
groups. In each panel, the harmonics are divided by the dotted line and are presented from the first to the seventh harmonic. Significant harmonics 
are marked with asterisk at the respective harmonics as analyzed with the Mann–Whitney U test. The first, second, sixth, and seventh harmonic of 
T11–T12 are significantly different (p = 0.0031, p = 0.0136, p = 0.0097, and p = 0.0330), and at L3–L4 for the sixth harmonic (p = 0.0330)
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impact on drug delivery strategies and the monitoring of 
ALS progression.
Key CSF dynamics findings
Timing of peak systolic CSF velocity at the FM was sig-
nificantly faster for the ALS group (p = 0.0136). Nota-
bly, one control subject had slower peak systolic CSF 
flow. However, because the flow amplitude was within 
the normal range, this subject was not considered an 
outlier as with ALS subject 102. Despite inclusion of 
this subject in the statistical analysis, timing at the 
FM was still found to be significantly faster in the ALS 
cohort. Overall, average CSF pulse wave velocity along 
the spine was elevated in the ALS group (473.19 cm/s) 
compared to the control group (347.41 cm/s) (Table 1). 
The average spatial–temporal distribution of the CSF 
PWV for all patients and controls is shown in Fig.  5. 
Elevated PWV may indicate an overall decrease in SSS 
compliance; however, arrival time of peak CSF flow 
was only significantly faster for the ALS group near the 
FM as evidence by analysis of peak CSF flow timing 
(Fig. 4). Peak systolic CSF flow magnitude occurred at 
a normalized distance of ~ 0.05 below the FM in peo-
ple with ALS and ~ 0.2 in controls (Fig.  7b). CSF flow 
amplitude in the ALS group was only greater at the 
C2–C3 location and smaller at C5–C6, T11–T12, and 
L3–L4 than in the control group. These differences 
may be further indication of an overall decrease in 
Fig. 7 Average values for the hydrodynamic parameters quantified for ALS (red) and healthy controls (blue) along the spine in terms of: a peak 
mean velocity, b peak flow rate, c Reynolds number and d hydraulic diameter (left y-axis) and Womersley number (right y-axis)
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SSS compliance with emphasis on the thoracolumbar 
region where changes in the spectral content of the 
normalized flow waveforms was most significant in the 
ALS group.
Reliability of MRI based measurements of CSF 
hydrodynamics
Due to the sensitivity of hydrodynamic parameters 
to both geometry and CSF flow, it is important that 
the measurement technique is robust enough to pro-
duce reliable results. In a previous study by our group, 
Khani et al. 2019, quantified scan-rescan reliability for 
geometric and hydrodynamic parameters in cynomol-
gus monkey for which geometric parameters displayed 
good follow-up agreement [12]. Hydrodynamic agree-
ment was also found to be positive although to a lesser 
correlative degree due to expected CSF flow variability 
at the 2-week follow-up scan. In cynomolgus monkeys, 
174 and 123 voxels were used to quantify the average 
axial SSS cross-section for geometric and CSF flow 
analysis respectively. For the present study, 551 and 
250 voxels were used to quantify the average axial SSS 
cross-section in human controls for geometric and 
CSF flow analysis respectively. In addition, the lower 
CSF flowrates observed in cynomolgus monkey are 
more difficult to measure than those found in humans. 
Thus, while scan-rescan reliability was not quanti-
fied in the current study, lower relative precision in 
cynomolgus likely result in a lower bounds of scan 
repeatability for identical techniques in humans. CSF 
PWV quantification has also been applied previously 
in healthy controls [30]. However, the exact test–retest 
reliability has not yet been quantified.
Inter-operator reliability of MRI based hydro-
dynamics has also been studied by our group [17]. 
T2-weighted MRI data collected using a 1.5  T mag-
net and 1.0 mm isotropic scan resolution of a healthy 
subject was analyzed by four operators using identical 
methods as the present study. The maximum coeffi-
cient of variation (CV) for cross-sectional area, peak 
systolic CSF flow, and Reynolds number were found 
to be 12.2%, 16.8% and 12.6% respectively. In the cur-
rent study, CV for cross-sectional area, peak systolic 
CSF flow, and Reynolds number were 29.8%, 26.2% 
and 41.5% respectively for healthy controls and 31.4%, 
25.6% and 17.8% in the ALS group. This suggests inter-
individual variability in and across groups is above the 
level explained by inter-operator variability alone.
Additionally, in  vitro studies have been performed 
by our group to quantify the reliability of MRI for 
CSF geometric and flow measurements. Yildiz et  al. 
2017, found a CV of 4.8% for peak CSF flow at a sin-
gle location [31] and Thyagaraj et  al. 2017, found a 
an average CV of 8% for peak CSF flow across several 
locations [32]. Geometric reconstruction was also ana-
lyzed by Thyagaraj et al. 2017, and found to be in good 
agreement with the digital. STL geometry used to cre-
ate the flow phantom; however, some systematic over 
estimation in reconstructed geometric variables was 
noted [32]. Overall, these observations provide further 
support for the robustness of the current method to be 
sufficient for observation of differences in and among 
groups.
Comparison of geometric results to previous studies
Review of CSF volume within the SSS was provided by 
Sass et  al. 2017, and averaged 80.0  cm3 for all studies 
reporting values of the complete SSS  [26]. In our study, 
CSF volume in the SSS averaged 97.3  cm3 for the ALS 
group, 10% less than the control group at 108.2  cm3. 
Qualitatively, this difference was not evident based on 
visual inspection, which revealed a similar degree of geo-
metric variability between both ALS and control cohorts 
(Fig.  2). Volumetric calculations are sensitive to small 
changes in segmentation accuracy which is itself depend-
ent on image resolution. While somewhat higher, our val-
ues for SSS volume are well within the range of reported 
values. Furthermore, when compared against average 
SSS volume from the small number of manual segmenta-
tions of healthy subjects, agreement is notable with those 
studies also averaging 108.2  cm3. Finally, trends in axial 
distribution of cross-sectional areas within our study for 
both spinal cord and dura show good similarity to Loth 
et al. 2001 [28], with peaks in SSS area located at the FM 
and lumbar enlargement (Fig. 3a, b). While T2-weighted 
MRI data for the full cranial volume was captured as part 
of the scanning protocol, we did not capture CSF flow 
around the brain or aqueduct of Sylvius. This was due to 
consideration of patient time in the scanner approach-
ing 1 h, and especially the sensitivity of the ALS group to 
prolonged supine position.
MRI based ALS biomarkers investigated in previous studies
The ideal ALS biomarker would have sufficient sensitiv-
ity and specificity for the syndrome, predict regional 
involvement and symptom spread, ability to differenti-
ate clinical phenotypes, and be based on easily accessible 
and affordable technology [33]. CSF-based biomarkers 
such as CSF hydrodynamics show promise because of the 
CSF’s innate proximity to the location of disease involve-
ment. Recent studies have shown that there is rapid 
exchange of CSF with the brain parenchyma during sleep 
acting to wash the brain [34, 35] as well as a possible 
glymphatic mechanism which removes waste products 
from the CSF [36]. Therefore, disruption of normal CSF 
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dynamics could, in principle, play a role in the progres-
sion of degenerative CNS disease.
While many MR imaging techniques have been used 
to investigate ALS biomarkers and disease progression 
[33, 37], the primary focus has been the CNS tissue, 
rather than the CSF surrounding that tissue. Conversely, 
research evaluating ALS molecular biomarkers in the 
CSF has been well established for many decades with a 
large number of possible disease biomarkers identified 
often in elevated levels. Disruption of the BBB has been 
implicated in a number of neurodegenerative diseases 
and is also possible to study through MRI imaging [38, 
39]. Coupling this understanding with CSF distribu-
tion and flow dynamics may provide further insight and 
predictors into the rate or mechanisms of the disease 
progression.
Progressive death of motor neurons in ALS leads 
to observable changes in the brain and spinal cord as 
highlighted by El Mendili et  al. 2019  [40]. Longitudinal 
studies have established a connection between cervi-
cal spinal cord atrophy and functional decline in ALS 
patients [41–43]. Additionally, reviews on the utility of 
various imaging techniques for visualizing changes in 
CNS have discussed a potential use in the diagnosis and 
tracking of ALS [33, 44, 45]. In particular, a study Sato 
et al. 2012 [24], utilized PCMRI to evaluate CSF pulsatil-
ity in 40 subjects with motor neuron disease as well as 14 
healthy controls. An average peak systolic CSF velocity 
of − 6.0 cm/s, − 5.4 cm/s and − 3.3 cm/s for was found 
for combined motor neuron disease, elderly controls and 
young controls, respectively. Furthermore, no significant 
difference of CSF pulse wave timing at C5 was found 
between the study groups. Flow velocities reported in 
the above study are somewhat higher than those found 
by our group (Fig. 7a). However, it should be noted that 
these measurements were taken at two small regions of 
interest bilaterally adjacent to the spinal cord. Our group 
has previously shown that CSF flow distribution is vari-
able across the spinal canal cross-section and can include 
localized flow “jets”   [13]. We therefore considered the 
average CSF velocity across the entire SSS cross-section 
which includes regions of both high and low flow rates. 
Finally, regarding CSF pulse wave timing, the aforemen-
tioned study by Sato and colleagues is consistent with our 
findings at the analogous location of C5/C6 finding no 
statistical difference. Importantly, our study contributes 
a novel analysis of hydrodynamics across the entire SSS 
geometry based on CSF flow measurements across the 
full SSS cross-section at multiple locations.
Potential implications for intrathecal ALS therapeutics
The proximity of CSF with the CNS tissue makes it a 
potential route for ALS treatment using intrathecal drug 
delivery. While IT drug delivery is a growing field, due to 
a gap in foundational knowledge and higher associated 
risks, IT devices and therapeutics are not common clini-
cally [46]. Intrathecal delivery baclofen is among the only 
IT therapy regularly prescribed for ALS where systemic 
side-effects are dose limiting and pain due to severe 
spasticity cannot be effectively managed by other means 
[47–49]. Ultimately, intrathecal baclofen is not a disease 
modifying treatment and symptomatic benefits need to 
be carefully titrated against retention of beneficial muscle 
tone [50].
At present, only two approved therapies, Riluzole and 
Edaravone, are shown to potentially produce modest 
delay in ALS progression, however neither is adminis-
tered intrathecally in humans [51]. Intrathecal delivery 
of Riluzole has been investigated in both Gottingen mini-
pigs and canine models [52, 53] with both studies demon-
strating higher Riluzole levels in the CNS while limiting 
the systemic dose that may lead to off-target side-effects. 
Additionally, gene therapy and therapies involving 
trophic factors to stimulate dying neurons [54, 55] have 
shown promise in rodent models. Other animal stud-
ies have also shown that human stem cells administered 
intrathecally delay the onset of symptoms and prolong 
survival in ALS transgenic mice [56]. The mechanism by 
which preservation, and in some cases, regeneration of 
motor neurons occurs appears to be due to production 
of growth factors and other neuroprotective compounds 
that can be found in CSF [56, 57]. Additionally, altera-
tion of the neurotoxic environment observed in ALS 
is another potential target for treating this devastating 
disease [58–60] and could be effected via CSF filtration 
[10, 11]. This could potentially improve the survivability 
of transplanted stem cells and improve effectiveness of 
other IT treatments. Overall, most potential IT thera-
peutic approaches for ALS remain experimental and are 
often based on specific induced forms of the disease in 
animal models. While the reduction of the above findings 
to clinical application is yet to be seen, the potential for 
CSF hydrodynamics to inform the design and application 
of new IT therapeutics and devices is still clear.
The observed differences in systolic and diastolic flow, 
volume of the SSS, and CSF geometric and hydrody-
namic properties are important for development of accu-
rate models for IT drug administration and manipulation 
of the spinal CSF environment. Several studies have used 
MRI data (frequently of healthy individuals) to derive 
in  vitro and computer-generated models for analyzing 
dispersion of compounds in the SSS and pulsatile flow is 
consistently indicated as one of the major contributors to 
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CSF mixing [12, 61–64]. One of our subjects (102) exhib-
ited nearly zero CSF flow while others had more modest 
decreases compared to controls. This subject also had a 
local SSS restriction in the cervical spine that was pre-
sent around the entire circumference of the spinal cord as 
well as suspected redundant nerve root syndrome in the 
lumbar spine (Fig. 2). While local variability in the cross-
sectional area of the SSS was noticeable in both groups, 
with the exception of ALS subject 102, there were no vis-
ible features which could consistently be correlated with 
CSF dynamics (Fig. 2). In the case of ALS subject 102, it 
is likely that the observed restrictions decreased the CSF 
pulsation along the entire spine. Because the rate of dif-
fusion within spinal CSF is many orders of magnitude 
slower than in advective mixing, this type of focal restric-
tion could have an important impact in context of IT sol-
ute transport [65].
Limitations
Several limitations exist in our study. Findings for both 
groups were based on a relatively small sample. Rar-
ity and variability of the disease combined with care-
ful screening against the ability to undergo a protracted 
MRI-scan presented a distinct challenge in finding par-
ticipants on a regional level. Secondly, our control group 
was not ideally matched against our ALS group and both 
groups included subjects with confounding conditions. 
While these factors negatively impacted the statistical 
power of the results in this study, it is straightforward to 
expand this data set in future with additional subjects. 
Furthermore, a longitudinal study would also allow com-
parison of any observations with disease progression.
Lastly, while raw data was collected at a relatively high 
resolution, micro anatomy such as nerve roots, and den-
ticulate ligaments were not possible to visualize. While 
important for specific transport dynamics, nerve roots 
did not have a large effect on unsteady CSF velocities as 
show in our previous computational study [27]. Similarly, 
flow measurements were made at only a few locations 
along the spinal canal and it was not possible to capture 
transient flow phenomena due to phase averaging. This 
was primarily a practical limitation of scan duration 
which was already at ~ 45 min.
Conclusion
This study characterized CSF flow dynamics along-
side geometric parameters in humans with ALS as 
well healthy controls. We found significant differences 
in peak systolic CSF flow timing at the FM, as well 
significant differences in the spectral content of CSF 
waveforms between ALS and control cohorts. More 
modest and non-significant differences in the CSF 
dynamics of our ALS group showed reduced CSF flow 
magnitude and increased PWV. While our study lacks 
sufficient power to draw definite conclusions regarding 
the differences we observed, we believe they deserve 
further investigation because of their potential impor-
tance related to intrathecal solute transport. In par-
ticular, a growing interest in IT drug delivery and the 
possible connection of trophic and neurotoxic factors 
in the CSF with disease progression warrant further 
study of CSF dynamics in the disease state. With the 
high degree of heterogeneity that exists among ALS 
cases it may be beneficial to conduct larger, longitudi-
nal studies to determine how changes in CSF flow cor-
relate with disease progression. This may contribute 
to the understanding of the pathologic progression of 
ALS, particularly if the onset of a neurotoxic CSF envi-
ronment and breakdown of CSF flow were to coincide.
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